<DOC>
	<DOCNO>NCT02229929</DOCNO>
	<brief_summary>The primary purpose study : - Evaluate safety pharmacokinetic profile repeat dos IV CR845 one week patient undergoing hemodialysis . ( Part A ) - This study also investigate whether repeat dos IV CR845 two week safe effective reduce intensity itch hemodialysis patient uremic pruritus ( Part B ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics IV CR845 Hemodialysis Patients , Its Efficacy Patients With Uremic Pruritus</brief_title>
	<detailed_description>Placebo-controlled</detailed_description>
	<mesh_term>Pruritus</mesh_term>
	<criteria>Inclusion criterion : Able provide write informed consent prior study procedure ; Able communicate clearly Investigator staff , able read understand study procedure ; Males females 18 year age old ; End stage renal disease ( ESRD ) patient hemodialysis least three month currently hemodialysis : At least three time per week ( Part A ) Three time per week ( Part B ) Has body weight â‰¤ 135 kg Part B : Patient selfreports daily near daily pruritus 6 week prior Screening ; Part B : Patient report Patient B Patient C profile Patient Selfcategorization Pruritus Disease Severity questionnaire Screening ; Part B : At end Runin Period : Patient complete rating bad itch intensity [ visual analog scale ( VAS ) ] least 8 time 14 VAS assessment ; Patient mean value &gt; 40 mm worst itch VAS one week Runin Period . Exclusion criterion : Known noncompliant dialysis treatment ( i.e. , history miss dialysis session due noncompliance past 2 month ) ; Anticipated receive kidney transplant study ; Known history allergic reaction opiates hive ( Note : side effect relate use opioids constipation nausea would exclude patient study ) ; Known suspected history Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) diagnose alcohol , narcotic , drug abuse dependence within 12 month prior Screening ; Acute unstable medical condition ( ) congestive heart failure [ New York Heart Association ( NYHA ) class IV ] , opinion Investigator would pose undue risk patient would impede complete collection data evaluability ; Serum alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) great 2.5X reference upper limit normal ( ULN ) , bilirubin great 4X ULN Screening ; Received another investigational drug within 30 day prior start Runin Period plan participate another clinical trial enrol study Part B : Has pruritus probably definitely attribute cause ESRD complication ( e.g. , patient concomitant pruritic dermatological disease cholestatic liver disease would exclude ) . ( Note : Patients whose pruritus attribute ESRD complication hyperparathyroidism , hyperphosphatemia , anemia , dialysis procedure prescription may enrol ) ; Part B : Has localize itch restrict palm hand determine Brief Itch Inventory diagram , complete Screening Period ; Part B : Has pruritus dialysis session ( patient report ) ; Part B : Has use gabapentin , calcineurin inhibitor , opioids ; antipsychotic ; systemic topical corticosteroid ( otic ophthalmic preparation ) ; sedatives ; hypnotic ; antianxiety agent selective serotonin reuptake inhibitor ( SSRIs ) ; tricyclic antidepressant &lt; 4 week prior start RunIn Period dose change within previous 30 day ; Part B : Is willing abstain use antihistamine ( oral , IV , topical ) 3 week ( start RunIn Period end Week 2 ) ; Part B : Not willing abstain making change topical nondrug treatment ( e.g. , emollient , cream , oil ) pruritus 3 week ( start RunIn Period end Week 2 ) ; Part B : Received ultraviolet B treatment within 30 day prior start Runin Period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pruritus</keyword>
	<keyword>uremic pruritus</keyword>
	<keyword>kappa opioid</keyword>
	<keyword>CR845</keyword>
</DOC>